Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:COM NASDAQ:ONC TSE:RVX NYSEARCA:SCYB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOMDirexion Auspice Broad Commodity Strategy ETF$27.65-0.4%$28.22$27.54▼$29.63$201.84M0.1958,931 shs78,307 shsONCBeOne Medicines$299.01-0.7%$263.99$155.75▼$308.87$33.00B0.27402,877 shs543,060 shsRVXResverlogixC$0.10+11.1%C$0.07C$0.04▼C$0.30C$19.79M0.71112,881 shs284,726 shsSCYBSchwab High Yield Bond ETF$26.26-0.6%$26.30$24.73▼$26.79$1.21B0.33460,670 shs726,223 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOMDirexion Auspice Broad Commodity Strategy ETF-0.36%-2.12%-1.36%-2.47%-3.99%ONCBeOne Medicines-0.70%+2.59%+22.38%+16.91%+29,900,999,900.00%RVXResverlogix0.00%-25.93%+122.22%+185.71%+100.00%SCYBSchwab High Yield Bond ETF-0.64%-0.87%-0.57%+1.51%+0.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOMDirexion Auspice Broad Commodity Strategy ETFN/AN/AN/AN/AN/AN/AN/AN/AONCBeOne Medicines0.7368 of 5 stars1.50.00.00.01.91.70.6RVXResverlogixN/AN/AN/AN/AN/AN/AN/AN/ASCYBSchwab High Yield Bond ETFN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOMDirexion Auspice Broad Commodity Strategy ETF 0.00N/AN/AN/AONCBeOne Medicines 3.00Buy$327.569.55% UpsideRVXResverlogix 0.00N/AN/AN/ASCYBSchwab High Yield Bond ETF 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RVX, ONC, SCYB, and COM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$321.00 ➝ $345.007/16/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$311.00 ➝ $349.006/27/2025ONCBeOne MedicinesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$313.00 ➝ $330.006/27/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$317.00 ➝ $321.006/27/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$311.005/8/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$312.00 ➝ $311.005/8/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$348.00 ➝ $350.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOMDirexion Auspice Broad Commodity Strategy ETFN/AN/AN/AN/AN/AN/AONCBeOne Medicines$3.81B8.60N/AN/A$34.10 per share8.77RVXResverlogixN/AN/AC$0.00 per share132.50C($0.23) per shareN/ASCYBSchwab High Yield Bond ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOMDirexion Auspice Broad Commodity Strategy ETFN/AN/A0.00∞N/AN/AN/AN/AN/AONCBeOne Medicines-$644.79M-$3.72N/A421.14N/A-9.40%-7.55%-4.42%8/6/2025 (Confirmed)RVXResverlogix-C$2.81M-C$0.02N/A∞N/AN/A6.06%-34.90%N/ASCYBSchwab High Yield Bond ETFN/AN/A60.28∞N/AN/AN/AN/AN/ALatest RVX, ONC, SCYB, and COM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025ONCBeOne Medicines-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOMDirexion Auspice Broad Commodity Strategy ETF$0.993.58%N/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/ARVXResverlogixN/A7.02%N/AN/AN/ASCYBSchwab High Yield Bond ETF$1.867.08%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOMDirexion Auspice Broad Commodity Strategy ETFN/AN/AN/AONCBeOne Medicines0.051.961.71RVXResverlogix-10.950.130.04SCYBSchwab High Yield Bond ETFN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOMDirexion Auspice Broad Commodity Strategy ETFN/AONCBeOne Medicines48.55%RVXResverlogixN/ASCYBSchwab High Yield Bond ETFN/AInsider OwnershipCompanyInsider OwnershipCOMDirexion Auspice Broad Commodity Strategy ETFN/AONCBeOne Medicines6.62%RVXResverlogix42.66%SCYBSchwab High Yield Bond ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOMDirexion Auspice Broad Commodity Strategy ETFN/A7.15 millionN/ANot OptionableONCBeOne Medicines11,000109.60 million102.34 millionN/ARVXResverlogix19197.94 millionN/ANot OptionableSCYBSchwab High Yield Bond ETFN/A46.10 millionN/ANot OptionableRVX, ONC, SCYB, and COM HeadlinesRecent News About These CompaniesSCYB: Passive High Yield ETF From SchwabJuly 16, 2025 | seekingalpha.comSchwab High Yield Bond ETF declares $0.1527 dividendJuly 1, 2025 | msn.com7 Lowest Expense Ratio ETFsJune 10, 2025 | money.usnews.comSCYB: Not The Time For High YieldMay 4, 2025 | seekingalpha.comSchwab High Yield Bond ETF declares $0.1586 dividendMay 2, 2025 | seekingalpha.comSchwab High Yield Bond ETF (SCYB) Dividend HistoryMarch 29, 2025 | nasdaq.comTrend Tracker for (SCYB)February 11, 2025 | news.stocktradersdaily.comN(SCYB) Trading SignalsJanuary 31, 2025 | news.stocktradersdaily.comNThese High-Yield Dividend Stocks Are Looking Better Than Bonds for SafetyJanuary 27, 2025 | msn.comWhen the Price of (SCYB) Talks, People ListenJanuary 20, 2025 | news.stocktradersdaily.comN(SCYB) Investment ReportDecember 30, 2024 | news.stocktradersdaily.comNWhen (SCYB) Moves Investors should ListenDecember 19, 2024 | news.stocktradersdaily.comNSchwab High Yield Bond ETF declares monthly distribution of $0.1489December 3, 2024 | msn.com(SCYB) Proactive StrategiesNovember 17, 2024 | news.stocktradersdaily.comNSchwab High Yield Bond ETF declares monthly distribution of $0.1667November 5, 2024 | msn.com(SCYB) Long Term Investment AnalysisOctober 17, 2024 | news.stocktradersdaily.comNWhere are the Opportunities in (SCYB)September 15, 2024 | news.stocktradersdaily.comNSchwab High Yield Bond ETF declares monthly distribution of $0.3075September 4, 2024 | msn.comSCHO: A Low-Risk, High-Yield Pick To Boost Your Dividend Portfolio's StabilityAugust 29, 2024 | seekingalpha.comTrading (SCYB) With Integrated Risk ControlsAugust 19, 2024 | news.stocktradersdaily.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesD-Wave Is Rising Again Despite Dilution—What’s the Deal?By Nathan Reiff | July 7, 2025View D-Wave Is Rising Again Despite Dilution—What’s the Deal?Palantir Gets Price Hike From Wedbush Amid High ValuationBy Chris Markoch | July 15, 2025View Palantir Gets Price Hike From Wedbush Amid High ValuationThese 3 Dividend Stocks Are Not Concerned With Tariff NoiseBy Thomas Hughes | July 11, 2025View These 3 Dividend Stocks Are Not Concerned With Tariff NoisePEGA Surges 14%: There's Still Time to Ride This GenAI InnovatorBy Leo Miller | July 27, 2025View PEGA Surges 14%: There's Still Time to Ride This GenAI Innovator3 Retailers Poised to Outmaneuver Tariff and Recession ConcernsBy Nathan Reiff | July 20, 2025View 3 Retailers Poised to Outmaneuver Tariff and Recession ConcernsRVX, ONC, SCYB, and COM Company DescriptionsDirexion Auspice Broad Commodity Strategy ETF NYSEARCA:COM$27.65 -0.10 (-0.36%) Closing price 08/1/2025 04:10 PM EasternExtended Trading$27.64 -0.01 (-0.04%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Direxion Auspice Broad Commodity Strategy ETF (COM) is an exchange-traded fund that is based on the Auspice Broad Commodity index. The fund tracks a broad-market index consisting of 12 commodity futures contracts, weighted by historical volatility, which can toggle to cash based on momentum. The fund will also hold short-term fixed income securities as collateral. COM was launched on Mar 30, 2017 and is managed by Direxion.BeOne Medicines NASDAQ:ONC$299.01 -2.12 (-0.70%) As of 08/1/2025 04:00 PM EasternBeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.Resverlogix TSE:RVXC$0.10 +0.01 (+11.11%) As of 08/1/2025 03:54 PM EasternResverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.Schwab High Yield Bond ETF NYSEARCA:SCYB$26.26 -0.17 (-0.64%) Closing price 08/1/2025 04:10 PM EasternExtended Trading$26.38 +0.13 (+0.48%) As of 08/1/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Schwab High Yield Bond ETF (SCYB) is an exchange-traded fund that mostly invests in high yield fixed income. The fund tracks an index of USD-denominated high-yield, US corporate bonds, selected and weighted based on market value. SCYB was launched on Jul 11, 2023 and is managed by Charles Schwab. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
